AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02282878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/Low Sodium Diet
Description: All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
Study NCT02282878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High/Low Sodium Diet
Description: All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
Study NCT04531774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECHARGE
Description: RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches.
Study NCT04531774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Study
Description: HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
Study NCT00703703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin tablets 15 mg once daily
Study NCT00703703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine extended release (ER) 4 mg once daily
Study NCT00703703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study NCT00972699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support and mentoring
Description: The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
Study NCT04134650 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin
Description: Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study NCT04134650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study NCT02991599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose
Study NCT02991599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study NCT04528485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sea swimming
Description: 8 sessions of swimming activities in the sea
Study NCT01929083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study NCT01312623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning at the left leg.
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
Study NCT04792450 — intervention group
Intervention type: DEVICE
Intervention: Thermography
Description: Measure Temperature using Thermal Camera
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 11 mg with epinephrine 100 mcg
Description: intrathecal bupivacaine 11 mg with epinephrine 100 mcg
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
Study NCT01264575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
Study NCT02692651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Description: Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
Study NCT01929083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive oral placebo two capsules once daily every evening for 7 days
Study NCT01929083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study NCT01929083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study NCT03415555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane blockade
Description: Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
Study NCT04792450 — intervention group
Intervention type: DEVICE
Intervention: Tympanic Thermometer
Description: Measure Temperature using Tympanic Thermometer
Study NCT01165710 — intervention group
Intervention type: OTHER
Intervention: Patients with Atrial Fibrillation (AF)
Description: Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
Study NCT03415555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
Study NCT03415555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Each patient will generally anesthetized and endotracheal tube will be inserted
Study NCT03415555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol will be given i.v. every 6 hours.
Study NCT01305447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Behaviour Maintenance
Description: Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
Study NCT04792450 — intervention group
Intervention type: DEVICE
Intervention: Forehead Thermometer
Description: Measure Temperature using Forehead Temperature
Study NCT01305447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Relapse prevention booklets
Description: Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
Study NCT01305447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Relapse prevention booklets
Description: Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
Study NCT01305447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact control
Description: No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
Study NCT05024006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Two intravenous loading doses, then daily infusion for 10 days
Study NCT05024006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Two oral loading doses, then orally twice daily for 10 days
Study NCT05024006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Orally twice daily for 14 days
Study NCT05024006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Daily injection for 6 days
Study NCT05024006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Orally twice daily for 10 days
Study NCT01812642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
Study NCT01812642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
Study NCT03106532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 0.25% ophthalmic solution
Description: 3 drops daily, 28 days
Study NCT03106532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 0.5% ophthalmic solution
Description: 3 drops daily, 28 days
Study NCT03106532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: 3 drops daily, 28 days
Study NCT04278794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Stroke Intervention (TCSI)
Description: Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention.
Study NCT00331760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT00331760 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Study NCT04574726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: static balance
Description: 30-second right and left unipodal static balance test
Study NCT04574726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static balance
Description: 30-second right and left unipodal static balance test
Study NCT04574726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic balance
Description: for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point
Study NCT04574726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic balance
Description: for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point
Study NCT05911490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged sitting
Description: In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
Study NCT05911490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking prolonged sitting
Description: In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
Study NCT00809133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
Study NCT00809133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC6 given on day 1 of 21 day cycle
Study NCT00809133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Escalating dose cohorts
Study NCT00809133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: MTD dose of part A
Study NCT00809133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 given on Day 1 of 21 Day cycle
Study NCT00809133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
Study NCT01350869 — intervention group
Intervention type: DEVICE
Intervention: Xience
Description: Patients with Xience
Study NCT00723333 — intervention group
Intervention type: PROCEDURE
Intervention: Reduced Intensity Conditioning (RIC) Allogenic Transplant
Description: Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
Study NCT02459080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-4208
Study NCT02459080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04792450 — intervention group
Intervention type: DEVICE
Intervention: 62 Max + Infra-red thermometer
Description: Measure Temperature using 62 Max + Infra-red thermometer
Study NCT02731313 — intervention group
Intervention type: BIOLOGICAL
Intervention: Trastuzumab
Description: Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
Study NCT03410238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Saferteens Brief Intervention
Description: A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
Study NCT02727088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
Study NCT02727088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy
Description: ablation of the whole dental pulp, preparation and filling of the whole root canal system
Study NCT03664037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
Study NCT03664037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
Study NCT02692651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
Study NCT04288232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal aflibercept Injection 2.0mg/0.05 ml
Study NCT02146144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM Peeling
Description: common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made
Study NCT00115323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving
Description: Problem solving intervention
Study NCT04074915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouth rinse
Description: Normal saline
Study NCT01429519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
Study NCT00115323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention control intervention
Study NCT05272436 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Reality Upper Limb Motor Impairment Rehabilitation
Description: Patients wore a VR headset while undergoing their physical rehabilitation at home
Study NCT05272436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Upper Limb Motor Impairment Rehabilitation
Description: Patients wore a VR headset while undergoing their physical rehabilitation at home